Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

TORRENT PHARMACEUTICALS LTD.
Business Statistics
and Quantitative
Technique Submission to : Mr. Tafheem
Submission by : Sushain Mahajan
MBA (PM), 2nd
Semester

INDEX
 Introduction.
 History.
 Mission , Vision and Values.
 List of API’s Manufactured.
 Analysis of Profits with specific calculations
using business statistics.

INTRODUCTION OF COMPANY:
 Torrent Pharma is in the Pharmaceuticals sector.
 Torrent Pharmaceuticals Ltd. is the flagship company
of the Torrent Group.
 Based in Ahmedabad , it was promoted by U. N.
Mehta initially as Trinity Laboratories Ltd. and was
later renamed to its current name Torrent
Pharmaceuticals Ltd.
 Torrent Pharmaceuticals operates in more than 50
countries with over 1000 product registrations
globally.
 The current market capitalisation stands at Rs
21,510.75 crore.

COMPANY MANAGEMENT INCLUDES:
• Ashish
Nanda,
• Bhavna
Doshi
• Samir
Mehra
• Markand
Bhatt,
• Pradeep
Bhargava,
• Shailesh
Haribhakti
• Sudhir
Mehta
Chairman Director
Independ
ent
Director
Executive
Vice
Chairman

HISTORY:
 1972 - The Company was incorporated on 15th July, as a Private Limited
Company by Shri Rajnikant C. Patel and his family members, and in June 1982,
the company was acquired by Shri Uttamlal N. Mehta.
 1989 - On 28th June the Company became a deemed Public Company under
the provisions of Section 43-A of the Act and by a Special Resolution passed on
25th July, 1992 at the Annual General Meeting, the Company became a Public
Limited Company within the meaning of Section 3(1)(iv) of the act and adopted a
new set of articles.
 1992 - Torrent Laboratories Limited, was amalgamated with the Company with
effect from 1st April by an order of the Honourable High Court of Gujarat, dated
22nd December.
 1993 - The Company proposes to modernize its present manufacturing facilities
located at Vatva and Chhatral to conform to the GMP requirements as also to
incorporate the latest technology available in the field.

 During the year, Torrent Medi-Systems Limited (TMSL) was merged with the
Company with effect from 1st April consequent to the scheme of amalgamation
approved by the Honourable High Court of Gujarat.
 1994 - The Company issued 1,74,144 Equity Shares of Rs.10 each as fully paid
up shares to the shareholders of TMSL after cancelling 9,300 Shares held by the
Company in TMSL.
 The Company was the first to launch ranitidine (Ranitin), nifedipine (Calcigard,)
atenolol (Betacard), domperidone (Domstal), diltiazem (Dilzem), amiodorane
(Cordarone), Lisinopril (Listril), etc. in the Indian market.
 During the year the Company launched a number of new products like Zirtin,
Tyklid, Flutamide and Topcef, all of which were well received in the market place.
 1995 - During the year the Company launched a number of new products like
Lomef (Lomefloxacin), Dilzem Inj. (Diltiazem), Depidol LA (Haliiperidiil
Decanoate) Oncoden (Ondancetron), Nimotide (Nimodipne), Pefcin (Pefloxacin)
which have gained wide acceptance in the pharmaceutical market.

 1999 - Among the new products launched recently included Nikoran IV for
critical care in cardiology and a novel drug approved for launch in the anti-
epileptic category.
 2002 - Torrent Pharma’s manufacturing facilities certified with ISO 14001:1996.
 Torrent’s R&D Centre received ISO/IEC 17025:1999 for its facilities by National
Accreditation Board for Testing and Calibration Laboratories (NABL).
 2003 - Torrent Pharma sets up a wholly owned subsidiaries in Germany and
Brazil.
 2004 - Torrent Pharmaceuticals Limited (TPL) has signed a non-exclusive
agreement with Dr. Reddy's Laboratories Limited (DRL) for licensing and
supplying the formulation of one of Torrent's blockbuster drug 'Domstal O' in the
Gastro Intestinal segment

 2005 - Torrent Pharmaceuticals signs agreement with Novo Nordisk,
Denmark to establish new, dedicated formulation and packaging facility
for Insulin, exclusively for Novo Nordisk.
 2006 - Torrent Pharma Receives USFDA Approval. Torrent’s Azuca
launches 2 new blockbusters, Pregeb and Piopod.
 2010 - The Board has recommended a dividend of Rs. 6.00 per equity
share having face value of Rs. 5/- each.
 2012 - The Board has appointed Haigreve khaitan as Additional Director.
 The Board has recommended a final dividend of Rs. 2.50 per equity
share.

MISSION, VISION AND VALUES OF TORRENT
PHARMACEUTICALS LTD.

Risperidon
e
Venlafaxine
Hydrochlori
de
Nicorandil
Sertraline
Hydrochlo
ride
Lamotrigi
ne
Nebivolol
Hydrochlo
ride
API’S MANUFACTURED

Ormeloxife
n
Hydrochlori
de
Ropinarole
Hydrochlori
de
Duloxetine
Hydrochlori
de
API’S MANUFACTURED

ANALYSIS OF PROFITS:
Following Financial Reports are used for the
analysis of profits of Torrent Pharmaceuticals
Ltd.
Quarter Ended
June 2013
Quarter Ended
September
2013
Quarter Ended
December
2013
Quarter Ended
March 2014
Quarter Ended
June 2014
Quarter Ended
September
2014
Quarter Ended
December
2014

• Profit : Rs. 149 crores
Quarter Ended June 2013
Quarter Ended September 2013
Quarter Ended December 2013

Quarter Ended March 2014

MEASURES OF CENTRAL TENDENCIES:
 A measure of central tendency is a single value that
attempts to describe a set of data by identifying the
central position within that set of data.
 As such, measures of central tendency are sometimes
called measures of central location.
 They are also classed as summary statistics.
 The mean (often called the average) is most likely the
measure of central tendency that you are most familiar
with, but there are others, such as the median and the
mode.

• The mean is equal to the sum of all
the values in the data set divided by
the number of values in the data set.
Mean:
• total no. of sample and ‘X’ correspond
to the observed valued.
Formula of mean is:

• The median is the middle score for a set
of data.
• When there is an odd number of
numbers, the median is simply the middle
number.
Median:
• Where ‘n’ is the number of samples
Formula of Median is:

• Mode of a set of data is the number with
the highest frequency.
Mode:
• A statistic used as a measure of the
dispersion or variation in a distribution or
set of data, equal to the square root of
the arithmetic mean of the squares of the
deviations from the arithmetic mean.
Standard Deviation:

Formula of Standard
Deviation is:

• => 149+113+158+224+256+198+167
7
=> 1265
7
=> 180.71
Therefore, the mean profit of
Torrent Pharmaceuticals Ltd. in 7
quarters is Rs. 180.71 crores.
Quarter Ended September
2013
Quarter Ended December
2013
•Profit : Rs. 224 crores

• Data in ascending order :
113,149,158,167,198,224,256
• [(n+1)/2]th data
• [ (7+1)/2]th = 4th observation
• 167 (Rs. in crores)
Therefore, the Median is Rs. 167
crores.
2013
2013

• The mode of a set of data is the
number with highest frequency,
here there is no repetition.
Therefore, there is no Mode.
2013
2013

Therefore, the standard
deviation is Rs. 48.53 crores.
2013
2013

BUSINESS IMPLICATION:
 Torrent Pharmaceuticals Ltd. have average
of Rs. 180.71 crores of profit after the
calculation.
 Torrent Pharmaceuticals Ltd. highest profits
has been Rs. 256 crores while lowest profit
has been Rs. 113 crores.

THANK YOU
Reference:
http://www.torrentpharma.com

Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (7)

Similaire à Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

Similaire à Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx (20)

Dernier

Dernier (20)

Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx